Antimyelin Oligodendrocyle Glycoprotein Demyelination
MOG antibody-related disorders, linked to demyelinating conditions like ADEM and NMOSD, are diagnosed by serum MOG-IgG positivity and CNS symptoms. Prognosis is generally favorable. Treatment includes high-dose methylprednisolone for acute attacks, and immunotherapies like mycophenolate or rituximab for relapsing cases to reduce frequency.
Chronic Relapsing Inflammatory Optic Neuropathy
Chronic Relapsing Inflammatory Optic Neuropathy (CRION) is a rare autoimmune optic neuritis, distinct from conditions like sarcoidosis, lupus, MS, or NMO. Diagnosed through MRI and exclusion of other causes, CRION treatment requires long-term immunosuppression, as glucocorticoid tapering often leads to relapse. Effective treatments include azathioprine, methotrexate, cyclophosphamide, and IVIG.
Acute Transverse Myelitis
Acute Transverse Myelitis, causing spinal cord inflammation, is treated with high-dose intravenous glucocorticoids and plasma exchange for severe cases. Cyclophosphamide may be beneficial, and treatment for secondary TM focuses on the underlying condition. Recurrent TM is managed with immunomodulatory therapies like mycophenolate or rituximab.
Neuromyelitis Optica
NMOSD, distinct from MS, is marked by AQP4 antibodies causing optic neuritis and myelitis. Diagnosis involves specific clinical criteria and antibody presence. Treatment includes methylprednisolone, plasma exchange, and immunotherapies like eculizumab and rituximab. Refractory cases may benefit from azathioprine or mycophenolate mofetil, with therapy typically lasting five years.
PML and JCV titers
Progressive multifocal leukoencephalopathy (PML), caused by John Cunningham virus reactivation, often follows immunomodulatory therapy or HIV. It presents with neurological deficits, diagnosed via MRI and lumbar puncture. Treatment focuses on restoring immune response, especially effective antiretroviral therapy in HIV. Prognosis is generally poor, with high mortality.
Multiple sclerosis Spasticity and Pain
Spasticity in MS, manifesting as resistance to movement or involuntary jerks, is managed with physiotherapy, exercises, and medications like baclofen and tizanidine. MS-associated pain, including trigeminal neuralgia and neuropathic pain, is treated with carbamazepine, gabapentin, pregabalin, and amitriptyline, tailored to the specific pain syndrome.
Multiple sclerosis Cognition and Ambulation issues
Cognitive impairment in MS, manifesting as inattention and memory issues, is managed with coping strategies, cognitive rehabilitation, and treating associated conditions like sleep disorders. Gait impairment is addressed through physical therapy, mobility aids, and possibly dalfampridine. Some DMTs may modestly benefit cognitive function.
Multiple sclerosis Bladder and Bowel issues
In MS, neurogenic bladder dysfunction causes urinary frequency and urgency, often worsened by infections. Treatment includes Oxybutynin for overactivity and Tamsulosin for sphincter dyssynergia, with botulinum toxin and neuromodulation as alternatives. Bowel issues are managed with diet, laxatives, and enemas, and severe faecal incontinence may require surgery.
Multiple sclerosis Tysabri protocol and monitoring
Natalizumab, given as a 300 mg IV infusion every four weeks, can cause infusion reactions, infections, melanoma, liver toxicity, and PML. Monitoring includes blood tests, JCV index, MRI, and TB screening. Discontinue for severe side effects, PML, lack of efficacy, or active disease. Extended dosing intervals may reduce PML risk.
Multiple sclerosis Tecfidera protocol and monitoring
Dimethyl fumarate, initially dosed at 120 mg twice daily and then increased to 240 mg, may cause flushing, gastrointestinal issues, lymphopenia, PML, and liver toxicity. Pre-treatment checks include blood tests, urinalysis, and MRI. Ongoing monitoring involves blood counts, liver function, and annual MRI. Discontinuation is advised for significant liver injury.
Multiple sclerosis Ocrevus protocol and monitoring
Ocrelizumab, used for B cell depletion, has risks of infusion reactions, infections, and lymphopenia. It's contraindicated in active hepatitis and post-live vaccines. Premedication and thorough pre-therapy assessments, including MRIs and blood tests, are essential. Ongoing monitoring involves blood tests, immune status, and annual MRIs.
Multiple sclerosis Betaseron protocol and monitoring
Interferon beta-1b for MS is given subcutaneously every other day, with dose titration. Common side effects include flu-like symptoms, liver dysfunction, and blood cell changes. Monitoring involves regular blood tests, liver function, and neutralizing antibodies. Adjust or discontinue for severe side effects or pregnancy.
Multiple sclerosis Avonex protocol and monitorin
Interferon beta-1a is administered intramuscularly weekly for MS, starting with a quarter dose, increasing to 30 μg. Side effects include flu-like symptoms, liver dysfunction, and blood cell changes. Monitoring involves regular blood tests, liver function, and checking for neutralizing antibodies. Discontinue for severe side effects or pregnancy.
Multiple sclerosis SPMS Management
For Secondary Progressive MS (SPMS), active disease management involves switching to treatments like Siponimod or Ocrelizumab. In cases with low activity, continuing or changing to Siponimod is advised, while discontinuation may be considered for inactive SPMS. Refractory cases might benefit from Cladribine, stem cell transplantation, or Methylprednisolone for acute attacks, tailored to individual responses and disease activity.
Multiple_sclerosis_PPMS_Criteria
Primary Progressive MS (PPMS) constitutes about 10% of MS cases and is characterized by a gradual increase in disability, often presenting as spinal cord syndrome. Diagnosed based on patient history and the McDonald criteria, it requires evidence of one-year progression and two out of three indicators: specific MRI lesions and cerebrospinal fluid oligoclonal bands. PPMS affects both genders equally, typically beginning around age 40.
Multiple sclerosis RRMS When to change disease modifying therapy
Changing Disease Modifying Therapy (DMT) in RRMS is considered for poor response, adherence issues, side effects, pregnancy, or COVID-19 risks. Alternatives are chosen based on the individual's response, with factors like JC Virus status and pregnancy affecting decisions. Some DMTs, particularly those causing lymphopenia, may heighten COVID-19 infection risks.
Multiple sclerosis RRMS Role of antibodies and MRIs for monitoring
Monitoring the response to Disease Modifying Therapies in Relapsing Remitting MS involves periodic MRIs to assess lesion progression and brain atrophy, and testing for specific autoantibodies like AQP4 and MOG-IgG. MRI is crucial for tracking new lesions and atrophy, while autoantibodies indicate specific disease aspects. Oligoclonal bands and CHI3L1 levels in CSF also provide prognostic information.
Multiple sclerosis RRMS Choice of Initial Disease modifying Drugs
Disease Modifying Therapies (DMT) for Relapsing Remitting MS (RRMS) include oral agents (dimethyl fumarate, teriflunomide), infusion therapies (natalizumab, ocrelizumab), and injections (interferon beta, glatiramer). Selection depends on disease severity, side effects, and patient preference. Oral agents are easy to use but require safety monitoring, while infusions target active disease but have higher risk profiles. Injections are safer but less potent. Treatment usually continues indefinitely.
Multiple sclerosis RRMS Latest Diagnostic criteria
Relapsing-remitting MS (RRMS) is diagnosed clinically, typically presenting in young adults with episodes of CNS dysfunction, such as vision loss or limb weakness. MRI reveals characteristic hyperintense white matter lesions. The McDonald criteria aid diagnosis, requiring evidence of multiple attacks and lesions. Additional tests like CSF oligoclonal bands, visual evoked potentials, optical coherence tomography, and autoantibody tests for AQP4 and MOG are used when presentations are atypical or insufficiently conclusive.
Multiple sclerosis Basic Management
Multiple Sclerosis, an immune-mediated CNS disease, has no cure but treatments delay progression. Relapsing-remitting MS is managed with oral, infusion, and injection therapies. Secondary progressive MS involves switching treatments, with options like siponimod. Primary progressive MS is treated with ocrelizumab, especially in younger patients. Acute attacks are managed with high-dose methylprednisolone.